CAS: 5470-65-5; 3-Bromo-4-Nitrophenol

上下游产品

CAS号591-20-8 3-溴苯酚 | CAS号577-19-5 邻溴硝基苯 | CAS号634603-83-1 3-bromo-4-nitro... | CAS号591-19-5 3-溴苯胺 | CAS号13362-38-4 2,5-Cyclohexadi... | CAS号7664-93-9 硫酸 | CAS号32338-02-6 2-溴-4-甲氧基苯胺 | CAS号165190-62-5 4-Benzyloxy-2-b... | CAS号74440-80-5 4-氨基-3-溴苯酚 | CAS号865886-83-5 2-Bromo-4-diflu... | CAS号79069-37-7 N-乙酰基-2-溴-4-甲氧基苯胺 | CAS号97868-28-5 N-(2-bromo-4-hy... | CAS号98447-30-4 3-溴-4-硝基苯甲醚 | CAS号57279-72-8 2-溴-4-乙氧基苯胺

2,4-二溴硝基苯置于ammonium Hydroxide,Cobalt(II) Acetate体系中,化学反应 2.0H,反应生成 3-溴-4-硝基苯酚
参考文献:一种中间体3-氟-4-硝基苯酚的合成方法
标题:一种中间体3-氟-4-硝基苯酚的合成方法
摘要:本发明公开了一种中间体3‑氟‑4‑硝基苯酚的合成方法,包括以下步骤:(1)将2,4‑二溴硝基苯与水混合后,加热至50‑60°C,在惰性气体保护下,加入醋酸钴搅拌混合均匀,之后滴加氨水进行回流反应,滴加完成后,继续搅拌回流反应1‑2H,反应完成后离心,分液,收集有机相,减压蒸馏,制得3‑溴‑4‑硝基苯酚和5‑溴‑2‑硝基苯酚的混合物,之后经水蒸气蒸馏,乙醚萃取,重结晶,分离同分异构体,制得3‑溴‑4‑硝基苯酚;(2)将3‑溴‑4‑硝基苯酚加入dmso中加入聚乙二醇‑400搅拌混合均匀后,加热至40‑50°C,向其中加入氟化钾,搅拌反应4‑5H,反应结束后,减压蒸馏,经重结晶后,制得3‑氟‑4‑硝基苯酚该合成方法操作简单,条件温和,副产物较少,产物纯度高,产物收率较高.

专利信息

专利号:US-12384788-B2
优先权日:2019-09-13
标 题 :1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
发明人：KOESTLER ROLAND; TASSEL JEAN; THORMANN MICHAEL; YEHIA NASSER; TREML ANDREAS; ALMSTETTER MICHAEL
权利人:ORIGENIS GMBH
摘要:The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine (example 49). (Formula (II):

专利号:US-12084422-B2
优先权日:2018-07-09
标 题 :Phenyl-n-quinoline derivatives for treating a RNA virus infection
发明人：SCHERRER DIDIER; TAZI JAMAL; MAHUTEAU-BETZER FLORENCE; NAJMAN ROMAIN; SANTO JULIEN; APOLIT CÉCILE
权利人:ABIVAX; CENTRE NAT RECH SCIENT; UNIV MONTPELLIER; INST CURIE
摘要:A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classificationwherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(â•?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

专利号:US-12421206-B2
优先权日:2018-07-09
标 题 :Aryl-n-aryl derivatives for treating a RNA virus infection
发明人：SCHERRER DIDIER; TAZI JAMAL; MAHUTEAU-BETZER FLORENCE; NAJMAN ROMAIN; SANTO JULIEN; APOLIT CÉCILE
权利人:ABIVAX; CENTRE NAT RECH SCIENT; UNIV MONTPELLIER; INST CURIE
摘要:A compound of formula (Ie):wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, agroup, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, agroup, agroup, a —PO(ORf)(OR′f) group, wherein Rf and R′f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.